The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus (2007)
Burgstaller, S.,
Kreil, S.,
Waghorn, K.,
Metzgeroth, G.,
Preudhomme, C.,
Zoi, K.,
...
We have investigated the hypothesis that constitutional genetic variation in IL-5 signalling may be associated with the development or severity of FIP1L1-PDGFRA-positive chronic eosinophilic...
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia (2007)
Jovanovic, J.V.,
Score, J.,
Waghorn, K.,
Cilloni, D.,
Gottardi, E.,
Metzgeroth, G.,
...
The FIP1L1-PDGFRA fusion gene is a recurrent molecular lesion in eosinophilia-associated myeloproliferative disorders, predicting a favorable response to imatinib mesylate. To investigate its...
Low-dose imatinib therapy leads to rapid induction of major molecular responses with achievement of molecular remission in FIP1L1 -PDGFRA associated hypereosinophilic syndrome (2006)
Jovanovic, J.,
Score, J.,
Waghorn, K.,
Reiter, A.,
Gottardi, E.,
Saglio, G.,
...
Sensitive detection of FIP1L1-PDGFRA fusion transcripts by real-time quantitative RT-PCR (RQ-PCR) reveals achievement of molecular remission in chronic eosinophilic leukemia treated with low-dose imatinib therapy (2005)
Jovanovic, J.,
Reiter, A.,
Cilloni, D.,
Gottardi, E.,
Score, J.,
Popp, H.,
...
The FIP1L1-PDGFRA fusion gene generated by a cryptic interstitial deletion at 4q12 is a recurrent molecular lesion in idiopathic hypereosinophilic syndrome (HES), that forms a basis for diagnosis of...
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML (2005)
Pearce, D.J.,
Taussig, D.,
Zibara, K.,
Ridler, C.M.,
Preudhomme, C.,
...
The nonobese diabetic/severe combined immunodeficient (NOD/SCID) assay is the current model for assessment of human normal and leukemic stem cells. We explored why 51% of 59 acute myeloid leukemia...
Oral sessions. Sensitive detection of FIP1L1-PDGFRA fusion transcripts by real-time quantitative RT-PCR (RQ-PCR) reveals achievement of molecular remission in chronic eosinophilic leukemia treated with low-dose imatinib therapy (2005)
Jovanovic, J.,
Reiter, A.,
Cilloni, D.,
Gottardi, E.,
Score, J.,
Popp, H.,
...
The FIP1L1-PDGFRA fusion gene generated by a cryptic interstitial deletion at 4q12 is a recurrent molecular lesion in idiopathic hypereosinophilic syndrome (HES), that forms a basis for diagnosis of...
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951 (2004)
CAVÉ, H,
SUCIU, S,
PREUDHOMME, C,
Poppe, Bruce,
ROBERT, A,
UYTTEBROECK, A,
...
HOX11L2 expression linked to t(5;14)(q35;q32) is not associated with poor prognosis in childhood T-ALL treated in EORTC trials 58 881 and 58 951 (2002)
CAVÉ, H,
SUCIU, S,
PREUDHOMME, C,
Poppe, Bruce,
ROBERT, A,
UYTTEBROEK, A,
...
Leukemic relapse is associated with a therapy-related karyotype, p53 deletion and chemoresistance in patients with advanced MDS/AML induced into remission with low-dose melphalan (2001)
Gelly, K,
Cunningham, J,
Salès, Matthieu; U0050716,
Preudhomme, C,
Fenaux, P,
Kerr, R,
...
Analysis of p16 gene deletion and point mutation in breast carcinoma.
Quesnel, B.,
Fenaux, P.,
Philippe, N.,
Fournier, J.,
Bonneterre, J.,
Preudhomme, C.,
...
We looked for p16 gene deletion by Southern analysis and p16 gene point mutation by single-stranded conformation polymorphism (SSCP) analysis and direct sequencing of DNA from fresh tumour samples of...